![Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease - Huntington's Disease News Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease - Huntington's Disease News](https://www.newshd.net/wp-content/uploads/2016/09/TEVA.jpg)
Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease - Huntington's Disease News
![Teva Reports First Quarter 2018 Financial Results - The Pharma Times | Pharma & Health Care News Portal Teva Reports First Quarter 2018 Financial Results - The Pharma Times | Pharma & Health Care News Portal](https://thepharmatimes.in/wp-content/uploads/2018/08/Capture-1280x720.jpg)
Teva Reports First Quarter 2018 Financial Results - The Pharma Times | Pharma & Health Care News Portal
![Teva Pharmaceutical Industries Limited 2022 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha Teva Pharmaceutical Industries Limited 2022 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha](https://static3.seekingalpha.com/uploads/sa_presentations/456/82456/slides/1.jpg?0)
Teva Pharmaceutical Industries Limited 2022 Q1 - Results - Earnings Call Presentation (NYSE:TEVA) | Seeking Alpha
![Teva, MedinCell announce positive results for registration trial of TV-46000/mdc-IRM for patients with Schizophrenia - Pharmaceutical Business review Teva, MedinCell announce positive results for registration trial of TV-46000/mdc-IRM for patients with Schizophrenia - Pharmaceutical Business review](https://www.pharmaceutical-business-review.com/wp-content/uploads/2021/01/1200px-TevaCanada7-1024x678.jpg)